Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock

CFO Thomas Catinazzo sold 17,717 RLAY shares on Apr 7, 2026 for $257,498 (prices $12.42–$13.46) and exercised 1,800 options at $5.22 then sold those at $15 for $27,000; he now directly owns 213,867 shares (incl. 13,075 RSUs) and 61,563 option shares. Relay reported Phase 1/2 data for zovegalisib + fulvestrant showing an 11.1-month progression-free survival (400mg BID with food) in PI3Kα‑mutated HR+/HER2‑ metastatic breast cancer, prompting Oppenheimer to reiterate Outperform ($14 PT), HC Wainwright to raise its PT to $19 (Buy), Raymond James to reiterate Strong Buy $19, and Guggenheim to raise its PT to $22. Shares trade near a 52-week high of $15 (≈+576% Y/Y); InvestingPro flags the stock as potentially overvalued but notes the company has more cash than debt.

Analysis

Small-cap oncology programs with biomarker-defined populations create outsized optionality: a favorable clinical signal often accelerates CDx adoption, increases bargaining power with large-cap acquirers, and shifts commercial opportunity from broad oncology sales into a high-margin, narrow-indication play. The non-obvious winners are not only potential acquirers (large pharmas who buy late-stage optionality) but also precision-diagnostics vendors, contract manufacturers able to scale a targeted oral oncology drug quickly, and specialty pharmacies that capture distribution economics for narrow-label assets.

Key risks are asymmetric: upside is binary (confirmatory data, regulatory path, or takeover) while downside is continuous (failed confirmatory study, class-level safety signals, or reimbursement pushback). Expect the timetable for material value realization to be 6–24 months depending on whether the company needs a registrational study or can be de-risked into a partnering/M&A process; in the interim, IV and retail flows will amplify moves, making short-term technicals noisy and increasing option-implied skews.

Consensus tends to over-index on buyout probability once a small biotech prints encouraging data; that compresses risk premia and creates opportunities to buy defined-risk asymmetric exposure or to harvest premium. A balanced approach — paid options to cap downside, calendar structures to sell time premium, or a long-idiosyncratic vs. short-broad-biotech pair — captures upside optionality while protecting against binary adverse outcomes and sector derisking.

Key Decisions for Investors

• RLAY — Buy a 9–15 month call spread sized to 2–3% of portfolio: buy a call ~30% OTM and sell a higher call ~80% OTM to create a capped, asymmetric payoff. Rationale: captures buyout/positive registrational optionality with defined max loss (premium); target 3x+ payoff if catalyst triggers within 12 months; stop the trade if implied volatility falls >40% from entry.
• RLAY — Equity + tail hedge (for higher conviction holders): accumulate a small long position (0.5–1% portfolio) and finance a portion of a 6–12 month 20–30% OTM protective put by selling 30–45 day 10–20% OTM calls. Rationale: collects premium to reduce cost of insurance while retaining upside; exit if share underperforms peer cohort by >25% over 60 days.
• Pair trade — Long RLAY vs short biotech index (IBB or similar) dollar-neutral for 6–12 months: size to 1% net portfolio risk. Rationale: isolates idiosyncratic upside from macro biotech beta; unwind if broad biotech leadership reasserts (sector breakout >15% in 30 days).
• Volatility harvest — If near-term IV spikes post-news, sell a small size near-term strangle (25–30 delta) while simultaneously purchasing a longer-dated protective strangle to cap tail risk. Rationale: monetize elevated short-term IV while keeping a long-duration hedge; limit notional to <1% portfolio to avoid large gamma exposure.